肺癌患者行全身骨扫描后再行胸部SPECT/CT的获益分析

目的:探讨肺癌患者行全身骨扫描后再行胸部SPECT/CT在诊断骨转移中的获益价值,筛选出SPECT/CT的最佳可获益人群。方法:选取2019年1月至2019年10月150例于广州医科大学附属肿瘤医院常规行全身骨扫描和胸部SPECT/CT的肺癌患者的临床资料。根据全身骨扫描和胸部SPECT/CT的诊断结果、病灶数量变化、定性诊断及随访结果,将SPECT/CT的获益程度分为无获益、一般获益和显著获益。收集所有患者的一般信息、临床信息和病灶影像信息,采用χ²检验分析上述变量与SPECT/CT获益程度之间的关系。结果:按照SPECT/CT获益程度,150例肺癌患者中,无获益41例、一般获益58例、显著获益51例。通过χ²检验发现,症状、数量、分布类型、累及部位、摄取水平是SPECT/CT获益评估的显著影响因素(χ²=7.849,P=0.020;χ²=19.567,P<0.001;χ²=17.053,P<0.001;χ²=7.643,P=0.022;χ<...

Benefit analysis of chest SPECT/CT after whole-body bone scan in lung cancer patients

  Objective  To evaluate the benefits of chest SPECT/CT in the diagnosis of bone metastasis after whole-body bone scan in lung cancer patients and to screen the optimal beneficiaries of SPECT/CT.  Methods  A total of 150 lung cancer patients who underwent routine whole-body bone scan and chest SPECT/CT in Affiliated Cancer Hospital and Institute of Guangzhou Medical University from January 2019 to October 2019 were enrolled in the study. The extent of benefit of SPECT/CT was stratified into no benefit, general benefit, and significant benefit based on the diagnostic results of whole-body bone scan and chest SPECT/CT, changes in the number of lesions, qualitative diagnosis, and follow-up results. General data, clinical information, and lesion imaging findings were collected for all patients. Finally, the relationship between these variables and the benefit from SPECT/CT was analyzed using the χ2 test.  Results  In terms of the extent of benefit of SPECT/CT, among the 150 patients with lung cancer, 41 patients showed no benefit, 58 patients showed general benefit, and 51 patients showed significant benefit. The chi-square test confirmed that symptoms(χ2=7.849, P=0.020), number of lesions (χ2=19.567, P < 0.001), type of distribution (χ2=17.053, P < 0.001), site of involvement (χ2=7.643, P=0.022), and imaging agent intake level (χ2=17.601, P=0.001) were found to be related to the benefit from SPECT/CT.  Conclusion  The necessity for thoracic SPECT/CT after whole-body bone scan in lung cancer patients should be evaluated by benefit assessment. The symptoms, number of lesions, type of distribution, site of involvement, and site of involvement were effective factors for evaluating the benefit of SPECT/CT.